Physician profile
Robert Klafter
NPI 1558360446
$1,465.27
in general payments reported to CMS, 2019-2025
24 companies · $587 in 2025
The $587 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $254 · 2024: $624 · 2025: $587.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,452 · Education: $13.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,452.23 |
| Education | $13.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $177.72 | 2023-2025 | Enhertu, Injectafer, Vanflyta |
| Pfizer INC. | $174.79 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $172.78 | 2023-2025 | Keytruda, Lynparza |
| Genzyme Corporation | $162.14 | 2024-2025 | |
| Gilead Sciences, INC. | $88.78 | 2023-2024 | |
| Janssen Biotech, INC. | $85.10 | 2023-2025 | Darzalex, Tecvayli, Rybrevant |
| Deciphera Pharmaceuticals INC. | $84.22 | 2023-2025 | Qinlock, Tgct, Romvimza |
| Pharmacosmos Therapeutics INC. | $77.75 | 2024-2025 | Monoferric |
| Bayer Healthcare Pharmaceuticals INC. | $52.46 | 2023-2025 | |
| Abbvie INC. | $52.28 | 2024 | |
| Glaxosmithkline, LLC. | $39.33 | 2024-2025 | Jemperli, Ojjaara |
| Array Biopharma INC | $38.93 | 2023-2025 | Braftovi, Mektovi, Lorbrena |
| Mirati Therapeutics, INC. | $32.72 | 2023-2024 | Krazati |
| Adc Therapeutics America, INC. | $31.46 | 2024 | |
| Tersera Therapeutics LLC | $27.26 | 2023 | Xermelo |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $27.03 | 2025 | Padcev |
| Servier Pharmaceuticals LLC | $24.95 | 2024 | |
| Novartis Pharmaceuticals Corporation | $18.52 | 2023 | |
| Genentech USA, INC. | $18.16 | 2024 | Itovebi, Tecentriq Hybreza, Tecentriq |
| Sumitomo Pharma America, INC. | $17.74 | 2025 | Orgovyx |
| Astrazeneca Pharmaceuticals LP | $17.15 | 2024 | Enhertu |
| Exelixis INC. | $15.84 | 2025 | Cabometyx |
| Geron Corporation | $14.34 | 2024 | Rytelo |
| Acrotech Biopharma INC. | $13.82 | 2025 | Beleodaq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Klafter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.